Delaney Geoff, Jacob Susannah, Barton Michael
Collaboration for Cancer Outcomes Research and Evaluation, Liverpool Hospital, Sydney, New South Wales, Australia.
Cancer. 2006 Jan 15;106(2):453-65. doi: 10.1002/cncr.21596.
In this one in a series of articles, the objective was to estimate the ideal proportion of patients with cancer who should receive radiotherapy at least once during the course of their illness based on the best available evidence. This estimate should be useful in planning for future radiotherapy facilities. Optimal rates of radiotherapy for patients with central nervous system (CNS) carcinoma, thyroid carcinoma, or carcinoma of unknown primary site (CUP) have not been studied previously.
A systematic review of evidence-based treatment guidelines for the treatment of CNS carcinoma, CUP, and thyroid carcinoma was undertaken. An optimal radiotherapy utilization tree was constructed for each of these malignancies depicting the indications for radiotherapy at various stages of disease. The proportion of patients who had clinical attributes that indicated a possible benefit from radiotherapy was calculated by adding epidemiological data to the radiotherapy utilization tree. The optimal proportion of patients who should receive radiotherapy was then calculated using specialized decision-analysis software. Sensitivity analyses using univariate analysis and Monte Carlo simulations were performed.
The optimal rates of radiotherapy utilization for carcinoma of the CNS, thyroid carcinoma, and CUP were 92%, 10%, and 61%, respectively. Comparison with actual rates of utilization in South Australia, Sweden, and the U.S. suggested an under-utilization of radiotherapy for CNS carcinoma and CUP. However, the actual rates of radiotherapy for thyroid carcinoma exceeded the optimal rate for some jurisdictions, although some data may have included radioactive iodine, which was not included in the current project.
It was possible to estimate optimal radiotherapy utilization rates based on evidence. This methodology allowed a comparison of optimal rates with actual rates to identify areas in which improvements in the evidence-based use of radiotherapy can be made, and it may provide valuable data for future radiotherapy service planning.
在本系列文章的第一篇中,目标是基于现有最佳证据估计癌症患者在病程中至少接受一次放疗的理想比例。这一估计对于规划未来放疗设施应会有所帮助。此前尚未对中枢神经系统(CNS)癌、甲状腺癌或原发灶不明癌(CUP)患者的最佳放疗率进行研究。
对CNS癌、CUP和甲状腺癌治疗的循证治疗指南进行了系统综述。针对这些恶性肿瘤中的每一种构建了一个最佳放疗利用树,描绘疾病各个阶段的放疗指征。通过将流行病学数据添加到放疗利用树中,计算出具有表明可能从放疗中获益的临床特征的患者比例。然后使用专门的决策分析软件计算应接受放疗的患者的最佳比例。进行了单因素分析和蒙特卡洛模拟的敏感性分析。
CNS癌、甲状腺癌和CUP的最佳放疗利用率分别为92%、10%和61%。与南澳大利亚、瑞典和美国的实际利用率比较表明,CNS癌和CUP的放疗利用不足。然而,甲状腺癌的实际放疗率在某些辖区超过了最佳率,尽管一些数据可能包括放射性碘,而这未包含在当前项目中。
基于证据估计最佳放疗利用率是可行的。这种方法允许将最佳率与实际率进行比较,以确定在循证放疗使用方面可改进的领域,并且它可能为未来放疗服务规划提供有价值的数据。